tldrdailynews.com logo

Gilead faces U.S. government in HIV prevention patent trial.

1 min read
Source: CNBC
Gilead faces U.S. government in HIV prevention patent trial.
Photo: CNBC
TL;DR

Gilead Sciences is facing allegations from the US government that the company violated patents for a crucial HIV prevention drug regimen, known as pre-exposure prophylaxis (PrEP), by reaping billions of dollars in PrEP sales without paying royalties to the Centers for Disease Control and Prevention (CDC). The trial in Delaware federal district court is expected to last six days. Gilead rejects the CDC's claims and argues that it is not obligated to apply for a license with the CDC or pay the agency any royalties.

Topics:businesshealthcare#gilead-sciences#healthcare#hiv-prevention#patent-infringement#truvada#us-government
Share this article
  1. Gilead Sciences battles U.S. government in court over HIV prevention patent  CNBC
  2. Trial imminent for U.S. lawsuit against Gilead over HIV treatment  The Washington Post
  3. Gilead, US set to clash at trial over PrEP drug patents  FiercePharma
  4. Gilead, US square off in billion-dollar HIV drug patent trial  Reuters
  5. A battle between Gilead and the U.S. government over patents on HIV prevention pills goes to trial  STAT

Want the full story? Read the original reporting

Read on CNBC